{"title":"Therapeutic effect of Sijunzi decoction on ulcerative colitis: A study based on in vitro functional experiments","authors":"Guobao Zhang, Wei Li","doi":"10.4314/tjpr.v22i9.12","DOIUrl":null,"url":null,"abstract":"Purpose: To investigate the efficacy of Sijunzi decoction (SJZD) against ulcerative colitis (UC) in vitro, and to unravel the probable mechanism of action.Methods: SEC-6 cells were exposed to lipopolysaccharide (LPS) in order to establish an ulcerative colitis model, and then treated with SJZD. CCK-8 assay was employed to evaluate cell viability, while cell apoptosis was determined by flow cytometry. Enzyme-linked immunosorbent assay (ELISA) and quantitative real-time polymerase chain reaction (qRT-PCR) were used to assess inflammation factors, viz, TNF-α, IL-1β and IL-6, whereas the expression levels of Bax, Bcl-2 and peroxisome proliferatoractivated receptors (PPARs) were evaluated by Western blot.Results: SJZD doses of 80 and 160 mg/L increased cell viability in LPS-induced SEC-6 cells, while Bcl2 and Bax expressions were regulated, and apoptosis inhibited at these doses (p < 0.05), indicating that SJZD attenuated cell apoptosis. Inflammation was also repressed by SJZD, based on the reduced expressions of TNF-α, IL-1β and IL-6 (p < 0.05). Furthermore, SJZD significantly increased PPARα level, thus enhancing cell viability, inhibiting apoptosis as well as inhibiting inflammation (p < 0.05).Conclusion: SJZD lowers cell damage, and inhibits cell apoptosis and inflammation through the activation of PPARα pathway, thus suggesting that SJZD is a potential therapeutic candidate for the treatment of ulcerative colitis.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"61 1","pages":"0"},"PeriodicalIF":0.6000,"publicationDate":"2023-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tropical Journal of Pharmaceutical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4314/tjpr.v22i9.12","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: To investigate the efficacy of Sijunzi decoction (SJZD) against ulcerative colitis (UC) in vitro, and to unravel the probable mechanism of action.Methods: SEC-6 cells were exposed to lipopolysaccharide (LPS) in order to establish an ulcerative colitis model, and then treated with SJZD. CCK-8 assay was employed to evaluate cell viability, while cell apoptosis was determined by flow cytometry. Enzyme-linked immunosorbent assay (ELISA) and quantitative real-time polymerase chain reaction (qRT-PCR) were used to assess inflammation factors, viz, TNF-α, IL-1β and IL-6, whereas the expression levels of Bax, Bcl-2 and peroxisome proliferatoractivated receptors (PPARs) were evaluated by Western blot.Results: SJZD doses of 80 and 160 mg/L increased cell viability in LPS-induced SEC-6 cells, while Bcl2 and Bax expressions were regulated, and apoptosis inhibited at these doses (p < 0.05), indicating that SJZD attenuated cell apoptosis. Inflammation was also repressed by SJZD, based on the reduced expressions of TNF-α, IL-1β and IL-6 (p < 0.05). Furthermore, SJZD significantly increased PPARα level, thus enhancing cell viability, inhibiting apoptosis as well as inhibiting inflammation (p < 0.05).Conclusion: SJZD lowers cell damage, and inhibits cell apoptosis and inflammation through the activation of PPARα pathway, thus suggesting that SJZD is a potential therapeutic candidate for the treatment of ulcerative colitis.
期刊介绍:
We seek to encourage pharmaceutical and allied research of tropical and international relevance and to foster multidisciplinary research and collaboration among scientists, the pharmaceutical industry and the healthcare professionals.
We publish articles in pharmaceutical sciences and related disciplines (including biotechnology, cell and molecular biology, drug utilization including adverse drug events, medical and other life sciences, and related engineering fields). Although primarily devoted to original research papers, we welcome reviews on current topics of special interest and relevance.